Seattle Genetics Inc.
) recently presented data on its antibody-drug conjugate (ADC)
candidates at the annual meeting of the American Association for
Cancer Research (AACR).
Preclinical data on SGN-CD33A showed significant antitumor
activity in acute myeloid leukemia (AML) models. Seattle Genetics
intends to file an investigational new drug (IND) application and
start a phase I study in 2013.
Another candidate, SGN-LIV1A, showed encouraging pre-clinical
data for breast cancer. Seattle Genetics will file an IND
application for SGN-LIV1A as well and start a phase I study in
2013 for breast cancer.
Seattle Genetics' sole marketed ADC product is Adcetris.
Adcetris is used for the treatment of patients with Hodgkin's
lymphoma (HL) after failure of autologous stem cell transplant
(ASCT) or after failure of at least two prior multi-agent
chemotherapy regimens in patients who are not suitable for ASCT.
Adcetris is also approved for the treatment of systemic
anaplastic large cell lymphoma (sALCL) after failure of at least
one multi-agent chemotherapy regimen.
Adcetris was approved by the US Food and Drug Administration
(FDA) in Aug 2011, got EU approval in Oct 2012 and marketing
authorization in Canada in Feb 2013.
ADCs have been attracting a lot of interest of late with major
companies entering into collaborations. Seattle Genetics has
collaborations with companies like
Roche Holding AG
) Genentech for the development of ADCs.
A few days back,
Astellas Pharma, Inc.
) announced a deal with Ambrx Inc. for the discovery and
development of novel ADCs.
Seattle Genetics carries a Zacks Rank #3 (Hold). Right now
Cleveland BioLabs, Inc.
) looks more attractive with a Zacks Rank #1 (Strong Buy).
ASTELLAS PHARMA (ALPMY): Get Free Report
CLEVELAND BIOLB (CBLI): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
SEATTLE GENETIC (SGEN): Free Stock Analysis
To read this article on Zacks.com click here.